PlainPharmaWatch

CMS Open Payments · Tool

HemoSonics LLC vs ALK-Abello, Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

HemoSonics LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,152, versus 403 for the other company. Its single largest recorded recipient represents 22.3% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

HemoSonics LLC
HHI 1,152 · top recipient 22.3%
Ranked #967 of 1,838 companies by HHI
ALK-Abello, Inc
HHI 403 · top recipient 11.5%
Ranked #1,377 of 1,838 companies by HHI

Payment Overview

Company A

HemoSonics LLC

Total Payments
$336.6K
% of Industry
0.0%
Transactions
237
Avg per Transaction
$1.4K
Recipients
219
Avg per Recipient
$1.5K
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting
Company B

ALK-Abello, Inc

Total Payments
$339.4K
% of Industry
0.0%
Transactions
4,525
Avg per Transaction
$75.00
Recipients
4,525
Avg per Recipient
$75.00
Payment Types
4
Top Payment Type
Honoraria

Highlighted values indicate the higher figure for each metric.

Total payments compared

HemoSonics LLC vs ALK-Abello, Inc - total reported payments in CMS Open Payments PY2024

ALK-Abello, Inc$339.4KHemoSonics LLC$336.6K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

HemoSonics LLC

Compensation for Services Other Than Consulting $37.1K

36.8%

Travel and Lodging $30.1K

29.8%

Consulting Fee $18.0K

17.9%

Food and Beverage $15.6K

15.5%

ALK-Abello, Inc

Honoraria $160.4K

47.3%

Food and Beverage $108.2K

31.9%

Consulting Fee $36.0K

10.6%

Travel and Lodging $34.8K

10.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

HemoSonics LLC

  1. 1

    MELISSA ANNE BURGER

    $22,464.88 · 4 txns

  2. 2

    JONATHAN CHOW

    $15,281.74 · 5 txns

  3. 3

    ASAD SHAH

    $13,732.33 · 6 txns

  4. 4

    JOSEPH GRIGGS

    $12,374.87 · 7 txns

  5. 5

    DALLAS HACK

    $4,497.48 · 3 txns

ALK-Abello, Inc

  1. 1

    Lara Gross

    $39,190.79 · 52 txns

  2. 2

    JACQUELINE EGHRARI-SABET

    $33,627.44 · 34 txns

  3. 3

    Michelle Yasharpour

    $24,098.42 · 40 txns

  4. 4

    Jonathan Malka

    $15,327.74 · 18 txns

  5. 5

    Gary Freed

    $13,975.82 · 12 txns

Summary Comparison

Metric HemoSonics LLC ALK-Abello, Inc
Total Payments $336.6K $339.4K
% of Industry Total 0.0% 0.0%
Transaction Count 237 4,525
Avg per Transaction $1.4K $75.00
Recipient Count 219 4,525
Avg per Recipient $1.5K $75.00
Payment Type Count 4 4
Top Payment Type Compensation for Services Other Than Consulting Honoraria

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.